Shantanu Narayen’s Form 4 activity across Adobe (ADBE) and Pfizer (PFE) paints a clear picture of a CEO who is monetizing equity rather than accumulating it. Over the tracked period, he recorded zero open-market purchases, while open-market sales totaled roughly $18.3 million. The most significant disposals came on April 28, 2026, when he sold ADBE shares in three tranches valued at approximately $2.53 million, $3.23 million, and $12.51 million. Those sales dwarf the only other cash-generating events, which were routine tax-withholding transactions (code F) tied to option exercises (code M) on quarterly vesting dates.
The compensation side of the ledger is equally telling. Narayen received ADBE stock awards (code A) with no reported value in January 2026, and Pfizer grants (code A) totaling roughly $355,000 across three separate awards in March, April, and June 2026. These are non-discretionary compensation events, not conviction buys. The only recent activity in the final weeks of the reporting window—July 15, 2026—consisted of option exercises and automatic share withholdings for taxes, none of which involved a cash outlay or a market purchase.
The directional bias is unambiguous: Narayen has been a net seller of ADBE, with his April 2026 sales representing the bulk of his realized value. His PFE holdings, by contrast, have grown only through scheduled grants. There is no evidence of him adding to either position with personal capital, and the absence of any code P transactions across 85 total filings underscores a posture of distribution rather than accumulation.
AI-assisted summary